Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982938 | 0.98 | KCNH2 (0.47) | KCNH2CNR2KDM4ELMNACYP3A4 | |
| SCHEMBL27759762 | 0.94 | CCR1 (0.42) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL1507007 | 0.86 | KDM4E (0.53) | KDM4ELMNACYP3A4TSHRSREBF2 | |
| SCHEMBL21820718 | 0.82 | SREBF2 (0.54) | KCNH2CNR2KDM4ELMNACYP3A4 | |
| SCHEMBL27644599 | 0.81 | KCNH2 (0.44) | KCNH2CNR2KDM4ELMNACYP3A4 | |
| SCHEMBL1328611 | 0.81 | LNPEP (0.48) | KCNH2KDM4ELMNACYP3A4TSHR | |
| SCHEMBL23815855 | 0.80 | KCNH2 (0.47) | KCNH2KDM4ELMNACYP3A4TSHR | |
| SCHEMBL31590556 | 0.80 | KCNH2 (0.47) | KCNH2KDM4ELMNACYP3A4TSHR | |
| SCHEMBL1030077 | 0.79 | KDM4E (0.47) | KCNH2KDM4ELMNACYP3A4TSHR | |
| SCHEMBL2553622 | 0.79 | CYP3A4 (0.46) | KCNH2KDM4ELMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | GE PING | 2008-05-08 | — | — | US | disclosed |
| US-7223778-B2 | 5-substituted-2-arylpyridines | NEUROGEN CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060217398-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | PFIZER INC | 2006-09-28 | — | — | US | disclosed |
| US-7087617-B2 | Substituted pyrimidine derivatives | PFIZER INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1625115-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | Pharmacia & Upjohn Company LLC (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050101613-A1 | Psychological disorders; anxiolytic agents; central nervous system disorders; antidepressants | PFIZER INC | 2005-05-12 | — | — | US | disclosed |
| WO-2004099148-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1392302-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | NEUROGEN CORPORATION | 2003-08-14 | — | — | US | disclosed |
| WO-2002096421-A1 | 5-SUBSTITUTED-2-ARYLPYRIDINES AS CRF1 MODULATORS | NEUROGEN CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030152520-A1 | 5-Substituted-2-arylpyridines | HTR5A, CRHR2, HTR2C | KCNH2 3681/4885CNR2 39/4885KDM4E 2266/4885 |
| US-20050101613-A1 | Psychological disorders; anxiolytic agents; central nervous system disorders; antidepressants | CRH, CRHR1, CRHR2 | KCNH2 3479/4885CNR2 20/4885KDM4E 3261/4885 |
| US-20060217398-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | CRHR1, CRH, CRHR2 | KCNH2 4384/4885CNR2 23/4885KDM4E 3662/4885 |
| US-20080107608-A1 | 5-Substituted-2-Arylpyridines | CRHR2, CRHR1, HTR2C | KCNH2 4176/4885CNR2 57/4885KDM4E 2577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.